T5O0 Stock Financial Analysis - bioXXmed AG (DB) Stock

Overview

BioXXmed AG, based in Switzerland, operates primarily in the biotechnology sector with a focus on developing medical treatments through genetic engineering and molecular biology techniques. The company's notable projects include the development of a novel gene therapy for treating rare inherited disorders, along with a proprietary biopharmaceutical platform aimed at enhancing the delivery of drugs to cellular targets. BioXXmed AG also collaborates extensively with academic institutions and industry partners to advance research and clinical trials aimed at addressing highly complex diseases such as cancer and neurological disorders. This strategic collaboration ensures a robust pipeline of innovative therapies, positioning BioXXmed AG as a leader in cutting-edge medical biotechnology solutions.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for bioXXmed AG as of 30 June 2024 is 0.00 MM.
The operating income for bioXXmed AG as of 30 June 2024 is -0.85 MM.
The net income for bioXXmed AG as of 30 June 2024 is -21.00 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2024-06-30	0.00	-0.85	-21.00
2024-03-31	0.01	-0.83	-20.97
2023-12-31	0.02	-0.81	-20.95
2023-09-30	0.02	-0.75	-10.80
2023-06-30	0.02	-0.69	-0.66
2023-03-31	0.02	-0.75	-0.75
2022-12-31	0.01	-0.82	-0.83
2022-09-30	0.03	-1.12	-2.38
2022-06-30	0.04	-1.42	-3.94
2022-03-31	0.04	-1.49	-4.00
2021-12-31	0.04	-1.57	-4.06
2021-09-30	0.03	-1.66	-2.90
2021-06-30	0.02	-1.75	-1.75
2021-03-31	0.03	-1.79	-1.79
2020-12-31	0.04	-1.84	-1.84
2020-09-30	0.04	-1.58	-1.62

Income Statement: EPS

The earnings per share basic for bioXXmed AG as of 30 June 2024 is -40.88.
The earnings per share diluted for bioXXmed AG as of 30 June 2024 is -40.88.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2024-06-30	-40.88	-40.88
2024-03-31	-40.83	-40.83
2023-12-31	-40.78	-40.78
2023-09-30	-21.03	-21.03
2023-06-30
2023-03-31	-1.45	-1.45
2022-12-31	-1.62	-1.62
2022-09-30	-4.64	-4.64
2022-06-30
2022-03-31	-7.78	-7.78
2021-12-31	-10.08	-10.08
2021-09-30	-7.21	-7.21
2021-06-30
2021-03-31
2020-12-31	-4.57	-4.57
2020-09-30	-4.02	-4.02

Cash Flow: Operations, Investing, Financing

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30	-0.58	-1.97	-0.16
2023-03-31	-0.75	-1.72	2.03
2022-12-31	-0.91	-1.47	4.22
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30	-1.61	-4.93	5.87
2021-03-31	-1.63	-4.87	5.94
2020-12-31	-1.66	-4.80	6.02
2020-09-30

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30

Management Effectiveness

The roa for bioXXmed AG as of 30 June 2024 is -0.98.
The roe for bioXXmed AG as of 30 June 2024 is -0.99.
The roic for bioXXmed AG as of 30 June 2024 is -182.19.
The croic for bioXXmed AG as of 30 June 2024 is 0.00.
The ocroic for bioXXmed AG as of 30 June 2024 is 0.00.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2024-06-30	-0.98	-0.99	-182.19	0.00	0.00
2024-03-31	-0.97	-0.98	-43.90	-5.69	-1.22
2023-12-31	-0.50	-0.50	-22.64	-5.69	-1.22
2023-09-30	-0.03	-0.03	-0.03	-0.13	-0.03
2023-06-30	-0.03	-0.03	-0.03	-0.13	-0.03
2023-03-31	-0.03	-0.03	-0.04	-0.02	-0.04
2022-12-31	-0.13	-0.13	-0.11	0.00	0.00
2022-09-30	-0.13	-0.13	-0.11	0.00	0.00
2022-06-30	-0.18	-0.18	-0.18	0.00	0.00
2022-03-31	-0.19	-0.19	-0.18	0.00	0.00
2021-12-31	-0.18	-0.19	-0.23	-0.04	-0.09
2021-09-30	-0.13	-0.13	-0.16	-0.04	-0.09
2021-06-30	-0.10	-0.10	-0.08	-0.03	-0.08
2021-03-31	-0.10	-0.10	-0.08	-0.03	-0.08
2020-12-31	-0.10	-0.10	-0.08	-0.02	-0.08
2020-09-30	-0.09	-0.09	-0.07	-0.05	-0.06

Gross Margins

The gross margin for bioXXmed AG as of 30 June 2024 is 1.00.
The net margin for bioXXmed AG as of 30 June 2024 is -1,873.08.
The operating margin for bioXXmed AG as of 30 June 2024 is -74.14.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2024-06-30	1.00	-1,873.08	-74.14
2024-03-31	1.00	-1,203.70	-46.33
2023-12-31	1.00	-569.94	-39.34
2023-09-30	1.00	-32.21	-33.41
2023-06-30	1.00	-32.21	-33.41
2023-03-31	1.00	-45.52	-46.06
2022-12-31	1.00	-84.07	-39.53
2022-09-30	1.00	-84.07	-39.53
2022-06-30	1.00	-88.53	-31.90
2022-03-31	1.00	-89.75	-33.54
2021-12-31	1.00	-90.95	-35.16
2021-09-30	1.00	-86.76	-49.56
2021-06-30	1.00	-78.37	-77.43
2021-03-31	1.00	-61.52	-60.78
2020-12-31	1.00	-51.09	-50.48
2020-09-30	1.00	-44.91	-43.40